Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01115426|
Recruitment Status : Completed
First Posted : May 4, 2010
Last Update Posted : May 4, 2010
|Condition or disease||Intervention/treatment||Phase|
|IGA Glomerulonephritis||Drug: Ramipril or losartan||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Long-term Treatment by Inhibitors of Angiotensin II at Low Doses in Non-nephrotic Proteinuric Patients With Pauciimmune and IgA Mesangioproliferative Glomerulonephritis|
|Study Start Date :||January 1997|
|Actual Primary Completion Date :||January 2007|
|Actual Study Completion Date :||January 2008|
anti-angiotensin II drugs
Never treated patients with non-nephrotic proteinuria (1-3 g/day), microhematuria, no-evidence of renal failure or other relevant diseases and with diagnosis of I-II stage IgA- or pauciimmune-MsPGN were considered eligible.
Drug: Ramipril or losartan
Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
Other Name: renin-angiotensin system (RAS) inhibitors
- renal function and proteinuria [ Time Frame: at the end of first year of observation ]
In particular, the end points of the study were a loss >20% of basal GFR and a decrease of basal daily proteinuria < 20% at the end of first year of observation.
GFR was calculated using both the abbreviated Modification of Diet in Renal Disease (MDRD) study equation and measured creatinine clearance. For each patient, a time-averaged (TA) proteinuria were calculated as an average of the mean of every-6month period's 24-hour proteinuria measurements.
- serum levels of creatinine [ Time Frame: at the end of first years of observation ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01115426
|"Mater Domini" Hospital|
|Catanzaro, Calabria, Italy, 88100|
|Study Chair:||Giorgio Fuiano, Professor||"Magna Graecia" University of Catanzaro, Nephrology Unit|